Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis Global MG Community turns Awareness into Action to ...

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging. Jonathan Strober ...

Myasthenia gravis is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fluctuating muscle weakness and fatigue in symptoms, long treatment ...

As the world's first innovative biologic drug targeting both BLyS and APRIL for the treatment of myasthenia gravis (MG), Telitacicept's approval not only brings new treatment options to patients ...

Myasthenia gravis is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fluctuating muscle weakness and fatigue in symptoms, long treatment cycles ...

The American Oncology Institute (AOI) in Guntur has successfully treated a rare and complex case of Myasthenia Gravis associated with Thymoma in a 61-year-old patient, Vattivela Adinarayana.

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include myasthenia gravis activities of daily living scale (MG-ADL) and quantitative myasthenia gravis (QMG) ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...